Meanwhile, TAMs not only secrete vesicle-packaged HIF-1α-stabilizing lncRNA to inhibit HIF-1 degradation, enhance glycolysis, and induce chemoresistance in breast cancer (195) but also inhibit T cell infiltration, resulting in decreased programmed death-ligand 1 expression in tumors, which compromises the tumor response to various anticancer therapies (245). This evidence concerns the gene HIF1A and breast cancer.